YishengBio Raises $130 Million in Series B Funding to Accelerate Pipeline Development and Commercialization
Summary
This round of funding will strongly support the expansion of the companys R&D center, accelerate our commercialization strategies including the clinical development of multiple vaccine candidates and the construction of biologics production facilities in China and Singapore. Other products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 for hepatitis B and PIKA YS-SC2-010, a prophylactic and therapeutic vaccine candidate against Covid-19 virus. Iris Wang, Managing Director of Orbimed Asia-Pacific, said, "Chinese biotech companies are playing an increasingly significant role in the innovation era of the whole world. As an existing shareholder of YishengBio, we are very glad to support the companys strategy in developing and commercializing innovative vaccines and therapeutic biologics once again and are very confident in the execution capability of the management team." It developed a PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Shingles, influenza, Coronavirus.